Accropeutics, a Suzhou, China-based clinical-stage biotechnology company that develops novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, raised $12M in Series B funding.
The round was led by Shenzhen Capital Group (SCGC), an existing investor, with participation from Morningside Ventures, also an existing investor, and new investors Leader Venture Investment (SZTI) and Hefei Sci-Tec Venture Capital (HFST).
The company intends to use the funds to expand operations and its business reach.
Led by CEO Dr. Xiaohu (Jason) Zhang, Accropeutics is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms of regulated cell death. The company has a portfolio of compounds in various stages of development, ranging from lead optimization to clinical testing. AC-101, a selective RIPK2 inhibitor, has completed Phase I clinical trials in Australia and China, and is currently undergoing a Phase Ib trial for Ulcerative Colitis (UC). AC-201, a selective TYK2/JAK1 inhibitor, has completed Phase I study in Australia and China, and is currently undergoing a Phase II trial for Psoriasis in China. AC-003, a selective RIPK1 inhibitor, has completed Phase I clinical trials in China and the United States as of August 2023, and is currently undergoing a Phase Ib clinical trial in aGVHD.
Accropeutics’ pipeline also includes assets in the research and pre-clinical stages of development. Accropeutics owns global rights for all of its assets, and boasts 23 issued patents in China, Japan, Korea, US and the EU.
FinSMEs
14/03/2025